Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…
Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Missouri: - Saint Francis Medical Center — Cape Girardeau, Missouri
- Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
- MU Health - University Hospital/Ellis Fischel Cancer Center — Columbia, Missouri
- Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
- Parkland Health Center - Farmington — Farmington, Missouri
Phase 3 Recruiting Industry
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…
Sponsor: Pfizer
NCT ID: NCT07144280
Sites in Missouri: - Missouri Cancer Associates — Columbia, Missouri
Phase 3 Recruiting Industry
The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a…
Sponsor: Pfizer
NCT ID: NCT06758401
Sites in Missouri: - Saint Luke's Hospital of Kansas City — Kansas City, Missouri
- Saint Luke's East Hospital — Lee's Summit, Missouri
Phase 3 Recruiting Industry
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …
Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in Missouri: - Research Site — Bridgeton, Missouri
- Research Site — Columbia, Missouri
- Research Site — Kansas City, Missouri
Phase 3 Recruiting NIH
This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgic…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07388524
Sites in Missouri: - Saint Francis Medical Center — Cape Girardeau, Missouri
Phase 3 Recruiting Network
This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approa…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06686771
Sites in Missouri: - Saint Francis Medical Center — Cape Girardeau, Missouri
- Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
- Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
- Washington University School of Medicine — St Louis, Missouri
- Siteman Cancer Center-South County — St Louis, Missouri
Phase 3 Recruiting Industry
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced o…
Sponsor: AstraZeneca
NCT ID: NCT06357533
Sites in Missouri: - Research Site — Kansas City, Missouri
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-muta…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06793215
Sites in Missouri: - Missouri Baptist Medical Center — St Louis, Missouri
Phase 2, Phase 3 Recruiting Industry
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…
Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in Missouri: - Missouri Cancer Associates — Columbia, Missouri
- SSM Health Cancer Care - St. Clare — Fenton, Missouri
Phase 3 Recruiting Industry
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in Missouri: - Ellis Fischel Cancer Center ( Site 0133) — Columbia, Missouri
- Lake Regional Hospital-Cancer Center ( Site 0123) — Osage Beach, Missouri
Phase 3 Recruiting Industry
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untr…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT06875310
Sites in Missouri: - Local Institution - 0685 — Fenton, Missouri
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07361510
Sites in Missouri: - Missouri Cancer Associates — Columbia, Missouri
Phase 3 Recruiting Industry
The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.
Sponsor: AstraZeneca
NCT ID: NCT06868277
Sites in Missouri: - Research Site — Bridgeton, Missouri
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.
Sponsor: Zai Lab (Shanghai) Co., Ltd.
NCT ID: NCT07218146
Sites in Missouri: - Missouri Cancer Associates — Columbia, Missouri
- Mercy South — St Louis, Missouri
Phase 3 Recruiting Industry
This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advance…
Sponsor: NovoCure GmbH
NCT ID: NCT06216301
Sites in Missouri: - Luminis Health Radiation Oncology - Anne Arundel Health System — Annapolis, Missouri
- University of Kansas Cancer Center - North — Kansas City, Missouri
- University of Kansas Cancer Center - Lee's Summit — Lee's Summit, Missouri
- University of Kansas Cancer Center - Overland Park — Overland, Missouri
Phase 3 Recruiting Industry
This study is designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
Sponsor: Daiichi Sankyo
NCT ID: NCT06203210
Sites in Missouri: - Mercy Clinic Oncology and Hematology Sindelar Cancer Center — St Louis, Missouri
Phase 2, Phase 3 Recruiting Industry
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07100080
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Phase 3 Recruiting Industry
Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma K…
Sponsor: Nuvalent Inc.
NCT ID: NCT06765109
Sites in Missouri: - Washington University Center for Advanced Medicine — St Louis, Missouri
Phase 3 Recruiting Industry
This is a randomized, two-cohort, open-label, phase 3, clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (cohort A) or prior failed Health Authority-approved antiprogrammed death-1 (PD-1) or anti-pr…
Sponsor: ImmunityBio, Inc.
NCT ID: NCT06745908
Sites in Missouri: - Barnes-Jewish Hospital - Siteman Cancer Center (Washington University - St. Louis) — St Louis, Missouri
Phase 3 Recruiting Industry
This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival w…
Sponsor: Boehringer Ingelheim
NCT ID: NCT07472517
Sites in Missouri: - HCA MidAmerica Division, Inc. — Kansas City, Missouri
Phase 2 Recruiting Network
This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the M…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06116682
Sites in Missouri: - Saint Francis Medical Center — Cape Girardeau, Missouri
- Parkland Health Center - Farmington — Farmington, Missouri
- University Health Truman Medical Center — Kansas City, Missouri
- University of Kansas Cancer Center - Briarcliff — Kansas City, Missouri
- University of Kansas Cancer Center - North — Kansas City, Missouri
Phase 2 Recruiting Network
This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer …
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06769126
Sites in Missouri: - University of Kansas Cancer Center - Briarcliff — Kansas City, Missouri
- University of Kansas Cancer Center - North — Kansas City, Missouri
- University of Kansas Cancer Center - Lee's Summit — Lee's Summit, Missouri
- Mercy Hospital South — St Louis, Missouri
- Mercy Hospital Saint Louis — St Louis, Missouri
Phase 2 Recruiting Academic/Other
This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to standard of care therapy alone in treating patients with non-…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07293247
Sites in Missouri: - Saint Francis Medical Center — Cape Girardeau, Missouri
Phase 2 Recruiting NIH
This phase II trial studies the effect of lutetium Lu 177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other places in th…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04665739
Sites in Missouri: - Missouri Baptist Medical Center — St Louis, Missouri
Phase 2 Recruiting Industry
The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation \[SC-CF\]) in combinat…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05498428
Sites in Missouri: - Washington University School Of Medicine — St Louis, Missouri